Improved method for tracking severity and potential spread of melanoma
January 13, 2016
A blood test that monitors blood levels of DNA fragments from dead cancer cells does a better job than the current standard test at tracking the severity and potential spread of metastatic melanoma, according to a study published in the journal Molecular Oncology (Jan. 2016; 10(1):157-165).
The standard test, in widespread use for decades to inform treatment decisions, measures blood levels of the enzyme lactate dehydrogenase (LDH). Levels of the enzyme tend to spike during aggressive tumor growth, but are also known to rise as part of other diseases and biological functions. The alternative test looks at levels of circulating tumor DNA (ctDNA) released into the blood when tumor cells die and break apart to spill their contents.
The NYU Langone Medical Center, New York City, team found that ctDNA levels in blood were elevated in 12 of 15 (80%) patients who were about to undergo treatment for their metastatic melanoma. By contrast, blood levels of LDH were elevated before therapy in seven of 23 patients (30%). Results also showed that ctDNA could detect cancer recurrence, as confirmed by X-ray or CT scan, in 22 of 26 (85%) patients tested and undergoing therapy, while LDH was elevated in only 14 patients (54%).
“Our study results show that circulating tumor DNA is a superior blood test for evaluating and tracking progression of metastatic melanoma,” said senior study investigator Dr. David Polsky, The Alfred W. Kopf, M.D. Professor of Dermatologic Oncology at NYU Langone, in a press release.
According to Dr. Polsky, an accurate blood test is preferred by doctors and many patients because it avoids the risk of infection and pain that accompany invasive needle biopsy and the radiation exposure that comes with X-ray or CT scans.
Thirty-one patients with inoperable metastatic melanoma were involved in the study, which took three years to complete. All had one of the two most common genetic mutations linked to the frequently fatal skin cancer, BRAF or NRAS. All had ctDNA and LDH blood tests performed after therapy, and most before treatment at NYU Langone. Normal blood levels of ctDNA were statistically determined by averaging results from 30 people who did not have melanoma.
Dr. Polsky said the growing number of immunological and targeted therapies for metastatic melanoma highlight the urgent need among cancer specialists for a simple but more accurate blood test to monitor the disease. Such a test would help to determine as early as possible when switching to an alternative therapy is warranted.
“A reliable blood test for tracking potential disease progression is preferred because blood tests offer feedback on what is happening throughout the body, while scans may not always visualize all parts of the body,” he said.
Among the study’s other key findings, noted Dr. Polsky, was that the ctDNA test was helpful in patients with small tumors whose melanoma had nevertheless spread. Specifically, ctDNA blood levels were elevated in five of seven such cases, while LDH levels were elevated in only one of 13.